enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $23.00.

Several equities analysts have weighed in on the stock. Oppenheimer reiterated an “outperform” rating and issued a $33.00 target price (up from $30.00) on shares of enGene in a report on Wednesday, November 12th. Raymond James Financial upgraded enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective on the stock in a report on Tuesday, November 11th. Citizens Jmp raised their target price on enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 12th. Citigroup reaffirmed a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of enGene in a report on Wednesday, December 3rd.

enGene Stock Down 0.3%

Shares of NASDAQ:ENGN opened at $9.97 on Wednesday. enGene has a 52-week low of $2.65 and a 52-week high of $12.25. The stock has a market cap of $667.89 million, a P/E ratio of -4.35 and a beta of -0.29. The business has a fifty day moving average of $8.99 and a two-hundred day moving average of $7.09. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.18). On average, research analysts expect that enGene will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On enGene

Several large investors have recently made changes to their positions in ENGN. Affinity Asset Advisors LLC acquired a new stake in enGene in the 2nd quarter valued at approximately $280,000. Millennium Management LLC boosted its position in shares of enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares during the period. Citadel Advisors LLC grew its stake in shares of enGene by 153.3% in the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after buying an additional 35,327 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after buying an additional 7,932 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of enGene in the 2nd quarter valued at $38,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.